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Abstract
Progesterone inhibits the proliferation of normal breast epithelial cells in vivo, as well as breast cancer cells in vitro. But the
biologic mechanism of this inhibition remains to be determined. We explored the possibility that an antiproliferative activity
of progesterone in breast cancer cell lines is due to its ability to induce apoptosis. Since p53, bcl-2 and survivin genetically
control the apoptotic process, we investigated whether or not these genes could be involved in the progesterone-induced apoptosis.
We found a maximal 90% inhibition of cell proliferation with T47-D breast cancer cells after exposure to 10 µM progesterone
for 72 h. Control progesterone receptor negative MDA-231 cancer cells were unresponsive to 10 µM progesterone. The earliest
sign of apoptosis is translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane and can be
monitored by the calcium-dependent binding of annexin V in conjunction with flow cytometry. After 24 h of exposure to 10 µM
progesterone, cytofluorometric analysis of T47-D breast cancer cells indicated 43% were annexin V-positive and had undergone
apoptosis and no cells showed signs of cellular necrosis (propidium iodide negative). After 72 h of exposure to 10 µM
progesterone, 48% of the cells had undergone apoptosis and 40% were annexin V positive/propidium iodide positive indicating
signs of necrosis. Control untreated cancer cells did not undergo apoptosis. Evidence proving apoptosis was also demonstrated
by fragmentation of nuclear DNA into multiples of oligonucleosomal fragments.
After 24 h of exposure of T47-D cells to either 1 or 10 µM progesterone, we observed a marked down-regulation of
protooncogene bcl-2 protein and mRNA levels. mRNA levels of survivin and the metastatic variant CD44 v7–v10 were also
downregulated. Progesterone increased p53 mRNA levels.
These results demonstrate that progesterone at relative high physiological concentrations, but comparable to those seen in
plasma during the third trimester of human pregnancy, exhibited a strong antiproliferative effect on breast cancer cells and
induced apoptosis. (Mol Cell Biochem 202: 53–61, 1999)
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Introduction
Tumor regression occurs when the rate of cell death is greater
than the rate of cell proliferation. Apoptosis is an active,
energy-dependent process in which a distinct series of
biochemical and molecular events leads to the death of cells
by specific signals which are mediated by two different
pathways: (A) a ligand to a plasma membrane receptor or
(B) negative induction by loss of a suppressor signal [1].
Apoptosis is mostly characterized by chromatin condensation
and DNA fragmentation [1]. However, the recent observation
that apoptosis can be induced in anucleate cells [2] implies
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that cytoplasmatic structures must control the apoptotic
process by at least two connected mechanisms (i) apoptotic
cells exhibit intact membranes until an advanced stage of the
death process; and (ii) apoptotic cells exhibit changes of their
plasma membrane that allow for their recognition and
elimination by adjacent cells. This recognition event is
mediated by phosphatidylserine (PS) residues [3], which
usually are only present on the inner leaflet of the plasma
membrane, but in apoptotic cells PS residues are aberrantly
expressed on the outer leaflet, hence allowing cytofluorometric
analysis of apoptotic cells with high affinity binding proteins
for PS.
Both bcl-2 and p53 genes and their products have both
been linked to the second apoptotic pathway [4, 5]. The
function of bcl-2 is to counteract the occurrence of apoptosis
and to prolong cell survival. Bcl-2 proteins are found as
dimers facing the cytosol predominantly in the outer
mitochondrial membrane with less in the endoplasmatic
reticular and nuclear membranes [6]. Survivin is a new
inhibitor of apoptosis protein (IAP) expressed during
development and in human cancer in vivo [7]. Expression of
survivin with other anti-apoptosis genes like bcl-2 translate
in drastically reduced apoptosis of cancer cells in vivo [8].
CD44, the prominent vertebrate cell surface receptor for
hyaluronan, exists in a variety of isoforms resulting from
alternative splicing of a single gene. Since the spliced variant
of CD44 expressing exons v7–v10 in tandem correlate with
increased cell motility, and with poor clinical prognosis in
several kinds of carcinomas [9], we investigated the effect
of progesterone on transcripts levels of this isoform.
It has been shown that the expression of bcl-2 in normal
human breast epithelial cells and the glandular endometrium
is hormonally regulated with maximal expression being at the
end of the follicular phase and a decrease seen during the
luteal phase [10, 11]. Thus the physiological role of bcl-2
expression and control of homeostasis in the normal breast
and endometrium should involve an upregulation by estradiol
and down-regulation by progesterone.
Indeed, a proliferative effect of estrogens on normal breast
cells as well as breast cancer cell lines has been reported [12],
and in a recent work Kandouz et al. [13] found that estradiol
stimulated and a progesterone inhibited bcl-2 protein
expression in cells of the breast cancer cell line T47-D.
Cells from the breast cancer cell line MCF-7 normally
express high levels of bcl-2 and low levels of p53 protein. In
addition p53 in those cells is nonfunctional because it is
segregated in the cytoplasm [14]. But more importantly, when
MCF-7 cells were transfected with mutant p53, the level of
bcl-2 was significantly reduced in comparison with the
parental MCF-7 cells, thus disclosing a possible mechanism
for an inverse correlation between the function of the two
proteins [15]. Additional support for this observation are the
experiments of Miyashita et al. [16, 17] showing the
existence of a negative response element in the bcl-2 gene
through which p53 either directly or indirectly transcriptionally
downregulate expression of this gene. Tumor suppressor p53
may also negatively regulate survivin gene expression in a
mechanism potentially similar to its role in transcriptional
repression of bcl-2 [18].
Our objective in this study was therefore to investigate the
level of p53 as well as levels of bcl-2, survivin and variant
CD44 v7–v10 transcripts primary in T47-D breast cancer
cells after treatment by progesterone. The results of our work
confirm the fact that the levels of bcl-2, survivin and variant
CD44 are downregulated and p53 upregulated by pro-




Progesterone-water soluble, propidium iodide and reagents
for cell culture were from Sigma (St. Louis, MO, USA). The
Ca2+-dependent phosphatidylserine (PS) binding protein
annexin V-FITC was from Pharmingen (San Diego, CA,
USA). 3H-thymidine was from New England Nuclear
(Boston, MA, USA). T47-D, MCF-7 and MDA-231 cell lines
were purchased from ATCC (Rockville, MD, USA).
Cell culture and hormone treatment
Cell cultures were done in a 5%-CO
2 
enriched atmosphere at
37oC in RPMI without phenol-red but containing 2 mM
glutamine and antibiotics plus 5%-steroid stripped FCS
(using dextran-coated charcoal). The effect of progesterone
on cancer was studied mainly in T47-D cells, which highly
express progesterone receptors [19]. We used progesterone
receptor negative MDA-231 tumor cells as controls to ensure
the effect of progesterone up to a relative high physiological
dose of 10 µM did not cause cell death in a non-specific
manner. Exponentially growing cells (~ 6 × 104/ml) were
treated with two different concentrations of progesterone for
durations of 24 or 72 h.
Proliferation assays
Breast cancer cells treated with two concentrations (1 µM or
10 µM) of progesterone were plated in triplicate wells of 96-
well microtiter plates and cultured 24 or 72 h. During the last
4 h of a culture period 1 µCi of 3H-thymidine was added to
each well. The cultures were harvested onto glass fiber disks
by a cell harvester. The disks were assayed for radioactivity
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in 3 ml Aquasol-2 in a β-counter. The data from 3 independent
experiments are presented as percentages ± S.D. of controls.
Cytofluorometric analysis of PS exposure on cells
undergoing apoptosis
After being treated with 10 µM progesterone for either 24 or
72 h, the cells were centrifuged, and the pellets washed
twice with cold PBS and then resuspended in binding buffer
(10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl and 2.5 mM
CaCl
2
). Five µl of Annexin V-FITC and 10 µl propidium
iodide (50 µg/ml) were added, and the cells were incubated
for 15 min at room temperature in the dark. Cells were then
analyzed for fluorescence using FACScan software (Becton
Dickinson).
Cytofluorometric analysis of bcl-2 protein
For the detection of bcl-2 protein, the cells were fixed with
0.25% formaldehyde for 30 min at room temperature, washed
once, and suspended in a PBS medium containing 10% fetal
bovine serum (FBS). Permeabilization of the cells was
achieved by adding 0.025% saponin (Sigma, St. Louis, MO,
USA) for 10 min before adding the antibody. The per-
meabilized cells were then incubated at 4°C with FITC-
conjugated hamster anti-human bcl-2 antibody (clone 6C8,
Ig2a isotype from Pharmigen, San Diego, CA, USA) for 30
min. Cells were then analyzed for fluorescence using FACScan
software (Becton Dickinson).
Assessment of DNA fragmentation
DNA fragmentation was determined by electrophoresis
according to a standard method previously described [20].
Semiquantitative reverse transcriptase (RT)-PCR analysis
A sensitive RT-PCR technique previously described by us
(21) was used to access the relative levels of mRNA (± 10–
25%) for specific gene transcripts. Briefly, poly-adenylated
RNA (poly A RNA) was extracted from T47-D cells cultured
24 h with 0, 1 or 10 µM of progesterone using the mRNA
isolation kit from Invitrogen (San Diego, CA, USA). The
mRNA (~ 1 µg) was used directly as template for first strand
synthesis of cDNA in a reaction mixture containing 1000 U
Moloney murine leukemia virus reverse transcriptase, 50 µM
random hexamer or oligo(dT)
12–14
, 50 mM Tris-HCl (pH 8.3),
75 mM KCl, 10 mM DTT, 3 mM MgCl
2
, 0.5 mM each of
dGTP, dATP, dTTP and dCTP all in 60 µl DEPC-treated water.
A sample not treated with RT was used as a control for
eventual contaminating DNA.
Reactions proceeded at 37°C for 60 min, after which they
were diluted 1:2 with DEPC-treated water. For hot start PCR
3 µl cDNA was added to 30 µl of a master mix containing
0.8 µM of each primer, 10 mM Tris-HCl (pH 8.3), and 50 mM
KCl. Water is added to the cDNA reactions to a final volume
of 40 µl. All reactions are overlayed with light mineral oil and
heated to 99°C. After 5 min, the reactions are cooled to 94°C
and a 10 µl vol. containing 7.0 mM MgCl
2
, 1 mM each of
dATP, dTTP, dGTP and dCTP, and 1.2 U taq polymerase is
added directly through the oil. Cycle parameters are: 95°C
for 60 sec, annealing at 58°C for 30 sec, 72°C for 30 sec, with
a 15 min final enzymatic primer extension at 72°C. Reactions
are cycled 28–32 times (vide infra) using an automated
thermocycler (Perkin Elmer Cetus). PCR products are
separated on agarose gels, stained in ethidium bromide,
visualized in UV light, photographed (Polaroid 667 film) and
scanned at 600 dpi in 8-bit (256 level) gray scale. A gray scale
value (GSV) was defined as the mean gray scale level (0–
255) multiplied by the total number of pixels in the scanned
PCR band, and used to indicate DNA content. These
measurements were performed using commercially available
software.
Upon PCR amplification of the serial dilutions of sample
cDNA, a concomitant decrease in PCR product was observed.
For semiquantitative comparisons template dilutions were
chosen to fall within the range in which input template
concentration correlated with the intensity of amplification
product. Similarly, a varying the number of PCR cycles did
not change the relative differences between samples. These
basic studies indicated that our PCR conditions never were
within the plateau phase of amplification. Plateau occurs at
higher cycles during PCR when band intensity no longer
increases or even decreases due to build up of higher
molecular weight products. Therefore, PCR reactions, in the
linear phase of amplification, are used for comparisons of
gene regulation following treatment with progesterone. The
following intron spanning amplimers (supplied commercially
by Operon Technologies, Alameda, CA, USA) were used;
human bcl-2 (GenBank accession #M14745) forward primer
was 5′-GGTGCCACCTGTGGTCCA-3′, and the reverse primer
was 5′-ACTTGTGGCCCAGATAGG-3′, amplifying a product
of 451 bp. Human p53 forward primer was 5′-GAGCCC-
CCTCTGAGTCAG-3′, and the reverse primer was 5′-GCA-
AAACATCTTGTTGAG-3′, amplifying a product of 375 bp.
Human survivin (GenBank accession #U75285) forward
primer was 5′-CCCTGCCTGGCAGCCCTTTC-3′ and the
reverse primer was 5′-CTGGCTCCCAGCCTTCCA-3′, amp-
lifying a product of 188 bp. Variant CD44 v7–v10 forward
primer (exon 10) was 5′-GATGGCATGAGGGATATCGCC-3′
and reverse primer (exon 14) was 5′-TTC-CTTCGTGTG-
GTGGTAATG-3′ amplifying a product of 501 bp. Human
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β-actin forward primer was 5′-GCTCTCTTCCA-GCCTTC-
CTTC-3′, and the reverse primer was 5′-AGAGCCACC-
AACCCACA-CAGAG, amplifying a product of 261 bp.
β-actin was an internal control to confirm equal amounts of
RNA were reversed transcribed and loaded on the gel.
Results
Progesterone inhibits proliferation of breast cancer cells
up to 90% in T47-D breast cancer cells
As shown in Fig. 1, proliferation of T47-D breast tumor cells
was inhibited by progesterone. After 24 h, 1 µM progesterone
inhibited 3H-thymidine uptake by 46 ± 12% (n = 3, p < 0.001)
and 10 µM by 63 ± 4% (n = 3, p < 0.001), respectively. After
72 h, 1 µM progesterone inhibited the uptake 56 ± 14% (n
= 3, p < 0.001) and 10 µM 90 ± 10% (n = 3, p < 0.001),
respectively. When MCF-7 breast tumor cells were cultured
24 h with 10 µM progesterone an inhibition of 35 ± 7% (n = 3,
p < 0.001), was found (this is not shown in Fig. 1). After 72 h
of culture, neither 10 nor 1 µM progesterone significantly
inhibited proliferation of the control MDA-231 cells.
Analysis of progesterone-induced apoptosis
T47-D breast tumor cells undergo apoptosis in response to
progesterone. After 24 or 72 h of culture, in the presence
of 10 µM progesterone the aberrant surface exposure of
phosphatidylserine (PS) was monitored by means of an FITC-
annexin V conjugate. Loss of membrane integrity was
measured by the ability of cells to exclude the DNA-binding
fluorescent dye propidium iodide. Representative data are
shown in Fig. 2.
As shown in Fig. 2B, 24 h progesterone treatment strongly
induced PS externalization and 43% of the cells displayed
a uniform high binding to annexin-FITC. After 72 h of
exposure to progesterone, 48% of the cells displayed binding
to annexin V-FITC (Fig. 2C). No binding to annexin V-FITC
was observed in the control population of cells (Fig. 2A).
Since it cannot be excluded that the appearance of annexin
V-FITC binding cells coincided with the appearance of cells
with ‘leaky’ membranes in these cultures, thereby allowing
annexin V to gain access to PS inside the cell, control and
progesterone treated cells were stained with annexin V-FITC
along with propidium iodide, to reveal cells that bound
annexin V have plasma membrane damage.
As documented in Fig. 2B, a negligible portion of the
cells after 24 h of exposure to progesterone were annexin
V-FITC+/propidium iodide+ (fluorescence 1 and 2, res-
pectively in Fig. 2), hence confirming annexin V was indeed
Fig. 1. The effect of progesterone on 3H-thymidine uptake into DNA of
T47-D human breast cancer cells. The cells were exposed to two
concentrations of progesterone as indicated during a culture period of 24
and 72 h, respectively. The percentages represent the mean of 3 individual
experiments. See text for statistics.
binding to the external PM leaflet of the cells undergoing
apoptosis. However, after 72 h of exposure to progesterone,
40% of the cells now stained positive for propidium iodide
indicating signs of necrosis (Fig. 2C). After 24 h exposure to
1 µM progesterone, 23% of the cells were annexin V-FITC
positive (data not shown). Apoptosis introduced after 72 h
exposure to 10 µM progesterone was confirmed by DNA
electrophoresis. DNA laddering and nuclear fragmentation,
characteristic of apoptosis, was observed only in cells treated
with progesterone for 72 h (Fig. 3, right lane).
Semiquantitative RT-PCR analysis of bcl-2, p-53 survivin
and variant CD44 v7–v10 transcripts in progesterone
treated T47-D cells
Expression of the apoptosis-related genes bcl-2 and p53 was
tested after cells were treated with 0, 1 and 10 µM progesterone
for 24 h. As shown in Fig. 4A, the mRNA level of bcl-2 was
markedly decreased after treatment with progesterone.
Inversely, the mRNA level of p53 was markedly increased.
Expression of survivin and variant CD44 v7–v10 was also
tested after cells were treated with 0, 1 and 10 µM progesterone
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for 24 h. As shown in Fig. 4B, the mRNA levels of survivin
were markedly decreased. Interestingly, transcripts of
variant CD44 v7–v10 were completely eliminated after
treatment with progesterone (Fig. 4B). Ratios of the relative
amounts of the target gene (i.e. bcl-2, p53, or survivin) to
constitutively expressed β-actin gene were calculated after
scanning of PCR products from the serial dilutions (1/2, 1/
4, 1/8) of template cDNA during the linear phase of amp-
lification (gels not shown). The relative densitometric
values (target gene/β-actin gene) were; for control bcl-2:
0.66 ± 0.06 (n = 3) vs. 10 µM progesterone bcl-2: 0.16 ±
0.03 (n = 3, p = 0.022), for control p53: 0.54 ± 0.17 (n = 3)
vs. 10 µM progesterone p53: 1.06 ± 0.08 (n = 3, p = 0.017)
and for control survivin: 0.61 ± 0.04 (n = 3) vs. 10 µM
progesterone survivin: 0.20 ± 0.05 (n = 3, p < 0.001).
Fig. 2. Annexin V binding and propidium iodide uptake in T47-D breast
tumor cells undergoing apoptosis vs. necrosis. T47-D cells were induced
to undergo apoptosis by exposure to none (A) or 10 µM progesterone for
24 h (B) or 72 h (C). Cells were stained with annexin V-FITC and propidium
iodide. Cells (10,000 per assay) were then analyzed by flow cytometry.
The percentage of annexin V+/propidium– in the lower right quadrant in B
is 43% (single cells undergoing apoptosis). The percentage of annexin V+/
propidium– in the lower right quadrant in C is 48%. The percentage of
annexin V+/propidium+ in upper right quadrant in B is < 2% and in C is
40% (cellular necrosis). Results are respresentative of 4 individual
experiments.
Fig. 3. DNA fragmentation in T47-D cells induced by 10 µM progesterone
after 72 h of culture (right lane), and untreated control T47-D cells (left
lane). Data are representative 3 experiments.
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Bcl-2 protein expression in progesterone treated T47-D
cells
To examine whether bcl-2 expression was correlated with the
sensitivity to progesterone induced apoptosis, intracyto-
plasmatic bcl-2 was analyzed after cells were treated with
10 µM progesterone for 0, 24 and 72 h. As shown in Fig. 5A,
T47-D cells expressed bcl-2, but a significant decrease in bcl-
2 expression was observed after exposure to progesterone.
Thus, the bcl-2 positivity dropped from 78 to 65% after 24 h
of exposure to progesterone (Figs 5A and 5B). After 72 h the
bcl-2 positivity dropped to 3% (Fig. 5C). Downregulation of
bcl-2 gene transcripts was detected by RT-PCR (Fig. 4); a
relative faint band (Fig. 4A, lanes 2 and 3) was observed after
24 h exposure to 10 µM progesterone, despite measurable
amounts of protein (65% positivity in Fig. 5B). This may
actually suggest that the bcl-2 protein in T47-D tumor cells
has a relative long half-life.
Discussion
In 1973 Sherman et al. [22] hypothesized that breast cancer
risk factors are the ‘manifestation of inadequate corpus
luteum secretory function’. In that light the absence of
sufficient cyclic progesterone secretion does provide a
situation favorable to estrogen mediated development of
mammary carcinoma.
Cowan et al. [23] categorized into two groups 1083 women
as to the cause of their infertility; those with endogenous
progesterone deficiency due to unovulatory cycles, and those
with ‘nonhormonal causes’. During a 33 year follow-up
period, it was found that women in the progesterone deficient
group had a 5.4 times the risk of premenopausal breast cancer
and 10-fold increase in deaths from all malignant neoplasms
compared to women in the nonhormonal group.
To further determine a possible association of progesterone
deficiency and breast cancer risk, we investigated the effect
of progesterone on the growth of breast tumor cells and
determined whether progesterone induces apoptosis in breast
B
A
Fig. 4. Representative data of 3 individual experiments showing effect of progesterone on steady state levels of bcl-2, survivin, variant CD44 v7–v10, p53
and β-actin mRNAs in T47-D cells as analysed by subplateau RT-PCR. The products of PCR amplification were separated by agarose gel electrophoresis,
stained with ethidium bromide, and visualized under UV light. Gels were photographed (Polaroid 667 film), and scanned using commercially available
software (see also Methods). A: cDNA were amplified with bcl-2 primers to produce a product of 451 bp (lanes 1–4), with p53 primers to produce a product
of 375 bp (lanes 5–8), with β-actin primers (internal control) to produce a product of 261 bp (lanes 9–12). T47-D breast cancer cells were exposed 24 h to 1
µM progesterone in lane 1, 5 and 9 or 10 µM progesterone in lane 2, 3,6,7,10 and 11. Untreated controls are shown in lane 4,8 and 12. Note progesterone
downregulates bcl-2 mRNA and upregulates p53 mRNA. M is a 100-bp DNA ladder for size comparison; B: cDNA were amplified with survivin primers to
produce a product of 188 bp (first 4 lanes), with variant CD44 v7–v10 primers to produce a product of 501 bp (middle 4 lanes), with β-actin primers to
produce a product of 261 bp (last 4 lanes). T47-D breast cancer cells were exposed 24 h to 1 µM progesterone (all lanes 1) or 10 µM progesterone
(all lane 2). Untreated controls are shown in lanes 3 and 4. Note progesterone downregulates survivin and eliminates variant CD44 v7–v10 levels
of mRNA.
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cancer cells and which apoptosis-related genes might be
involved. Here, we report that progesterone in vitro inhibits
proliferation of at least two breast tumor cells lines, T47-D
and MCF-7. Progesterone inhibition was dose dependent with
a maximal 90% inhibition observed after 72 h of culture in
the presence of 10 µM progesterone. Growth of progesterone
receptor negative control MDA-231 breast cancer cells was
not affected by progesterone at any of the concentrations
used, hence excluding any progesterone induced non-specific
cell death.
Our results confirm data reported by other investigators on
breast cancer cell lines in culture [24, 25], especially the
strong progesterone receptor positive T47-D cells [19]. It is
important to note, however; that normal breast epithelial cells
respond in the same way to progesterone. Thus, it was found
[12] that the progesterone R5020 at a concentration of 1 µM
inhibited > 90% the growth after 72 h in culture. Estradiol at
a concentration of 0.01 µM stimulated proliferation of normal
breast epithelial cells, which was blocked > 90% by 0.1 µM
progesterone.
Also, in vivo studies show that progesterone decreases the
mitotic activity of normal human breast epithelial cells.
Thus, Chang et al. [26] in a double-blind randomized study
topically applied progesterone, estradiol, or a combination of
estradiol and progesterone, or placebo daily for period of a
10–13 days, exactly the same duration as a normal luteal
phase in vivo. In the surgically biopsied breast epithelium, it
was found that increased concentration of estradiol increased
the number of cycling epithelial cells; whereas, increasing
concentrations of progesterone significantly decreased the
number of cycling epithelial cells. Progesterone reduced
estradiol-induced proliferation. This is an important ob-
servation that recently was confirmed by Foidart et al. in a
double-blind randomized study [27]. It indicates that natural
progesterone replacement (NPR) can prevent normal breast
epithelium from transforming into estradiol-induced hyper-
plasia. Similar, Barrat et al. [28] found that sustained levels
of progesterone in breast tissue maintained for > 10 days,
decreased the mitotic activity in the normal breast epithelial
cells.
Collectively, these data strongly support the concept, as is
also the case in endometrium, that during a normal 14 day
luteal phase, progesterone controls the human breast
epithelial cell cycle. Such control could be mediated by
apoptosis. Inversely, to these observations some synthetic
progestins in oral contraceptives, e.g. 19-nortestosterone,
have been reported to stimulate proliferation of breast cancer
cells, but it should be emphasized that many progestins have
estrogenic properties with the ability to activate the estrogen
receptor, but not progesterone receptor. This explains their
growth-stimulatory potential [29, 30]. In a broader context,
an evaluation of the ‘total estrogenicity’ of combinations
of synthetic progestins may provide clues likely to be
Fig. 5. Cytofluorometric analysis of cytoplasmatic bcl-2 protein in T47-D
tumor cells exposed to 10 µM progesterone for 24 h (B), or 72 h (C). (A) is
control. Within 24 h bcl-2 positivity dropped from 78 to 65% (A and B).
Within 72 h bcl-2 dropped from 78 to 3% (A and C).Representative data of
3 individual experiments.
60
detrimental to women, which is documented in a recent study
[31], where medroxyprogesterone (progestin) contrary to
natural progesterone, stimulated the development of coronary
vasospasm in ovariectomized rhesus monkeys.
A critical event during programmed cell death, appears to
be the acquisition of plasma membrane changes. In the
apoptotic cells with still intact cell membranes there is
observed a loss of phosphatidylserine bilayer asymmetry
[32]. This effect is also obtained in anucleate cells, indicating
that the nucleus does not intervene in the sequence of initial
events coupled to phosphatidylserine exposure. Thus,
phosphatidylserine residues, which usually are only present
on the inner leaflet of the plasma membrane, are expressed
on the outer leaflet of apoptotic cells in a sequence followed
by full-blown DNA fragmentation [3].
The aberrant exposure on the outer plasma membrane leaflet
of phosphatidylserine can be quantified cytofluorometrically
at the single-cell level as an FITC-annexin V conjugate. Such
observations have been reported in Jurkat cultures where
apoptosis was induced by Fas ligation [32].
Phosphatidylserine exposure on apoptotic Jurkat cells
preceded the increase in membrane permeability and nuclear
condensation. Of interest, was the observation that the effector
element(s) responsible for activating phosphatidylserine
translocase activity was likely to be downstream of bcl-2;
because the morphological features of apoptosis were
prevented when bcl-2 was overexpressed in transfected cell
lines [32].
Several studies have concluded that progesterone can
induce apoptosis in normal breast and endometrial tissue [11,
12]. Of great importance, recently, Bu et al. [33] reported
progesterone at a concentration of 10 µM induced apoptosis
in two ovarian carcinoma cell lines. We found, that 43% of
T47-D breast tumor cells were annexin V positive after
exposure to 10 µM progesterone for 24 h, indicating apoptotic
pathways were activated in these tumor cells. After 72 h of
culture in the presence of 10 µM progesterone, 48% of the
T47-D cancer cells were annexin V-FITC positive, but 40%
of the cells now being propidium iodide positive is a
significant sign of ‘leaky’ membranes (necrosis). Similar
studies using breast cancer cells, to the best of our knowledge,
have not been reported, heretofore.
Apoptosis is an active process which depends on the
expression of specific sets of genes. Among these genes, p53
can induce apoptosis; and bcl-2 inhibits apoptosis [4, 5]. It
is of interest to note, that Lee et al. [34] analysed 101 invasive
ductal carcinomas of the breast for the expression of bcl-2
and p53. These investigators found reciprocal expression of
bcl-2 and p53 present in 71.3% of cases, and suggested bcl-
2 could be an estrogen-related protein.
Bu et al. [33] found by Northern blots that exposure of
ovarian tumor cells to 10 µM progesterone for 72 h also
strongly increased the levels of p53 mRNA. Combined with
our data on breast cancer, we speculate that progesterone
occurs naturally as a homeostatic control of normal pro-
liferation in healthy young women. Cancer then, together
with other factors could be a natural body-wide phenomenon
when anovulation becomes prevalent.
Using a sensitive, semiquantitative RT-PCR technique, we
found 1 and 10 µM progesterone strongly down-regulated
expression of bcl-2 and up-regulated expression of p53 at the
transcriptional level. A similar inverse relationship of bcl-2
and p53 at the translational level has been reported by Haldar
et al. [15], who found 8 of 12 breast cancer cell lines had an
inverse and reciprocal level of expression of those two genes;
suggesting that p53 determines bcl-2 down-regulation. This
was confirmed in MCF-7 cells transfected to express high
levels of p53 protein, which significantly reduced the level
of bcl-2 protein. Of note, is that others [13] have reported
progesterone R5020 down-regulates expression of bcl-2
protein in T47-D breast cancer cells. Apoptosis in this study
was not investigated.
We examined the bcl-2 protein expression in T47-D cells
after 24 and 72 h exposure to 10 µM progesterone, because
the protein of proto-oncogene bcl-2 inhibits apoptosis [6]. As
shown in Figs 4 and 5, we observed a significant correlation
between progesterone induced downregulation of bcl-2 gene
transcripts and bcl-2 protein, suggesting this protein might
regulate progesterone-mediated apoptosis in T47-D tumor
cells. Expression of p53 and survivin proteins were not
examined in this study.
CD44 functions in cell motility, lymphocyte homing, and
in a variety of cell-matrix interactions. Alternatively spliced
variants of CD44 are associated with enhanced invasiveness
of cancer cells. Particular the isoform expressing exons v7–
v10 in tandem show increased metastatic potential [35].
Elimination of an entire viable region of CD44 (exons v7–
v10) was observed following 24 h incubation with 10 µM
progesterone. Similar observation has not been reported
before and the molecular implications of this finding, remain
to be determined.
Bcl-2 and p53 are established modulators of tumor cell
progression and viability. We found that the expression of
anti-apoptotic gene survivin correlated with the expression
of bcl-2. Both genes were downregulated by progesterone
which translated in drastically enhanced apoptosis of T47-
D tumor cells. The significant coassociation of survivin and
bcl-2 in T47-D breast cancer cells imply a strong mechanism
of apoptosis inhibition, which potentially contribute to tumor
progression and multidrug resistance. The intriguing finding
of this study is the novel role of progesterone in transcriptional
repression, potentially involving apoptosis inhibitors like bcl-
2 and survivin, which may provide important insights into a
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